Prof. Yohann Loriot is a university professor and hospital practitioner at Gustave Roussy Cancer Campus, France, serving as Deputy Head of the Department of Therapeutic Innovation and Early Trials (DITEP) and coordinator of the UNLOCK programme, which focuses on analysing mechanisms of action and resistance to innovative therapies. A specialist in bladder and urothelial cancers, he teaches medicine at the University of Paris-Saclay and holds a medical doctorate from Pierre-et-Marie-Curie University and a PhD in anti-tumour pharmacology from the University of Paris-Saclay. In 2024, he was awarded his Habilitation à Diriger des Recherches (HDR). He joined Gustave Roussy in 2009, spending a year at the Vancouver Prostate Centre studying androgen receptor resistance mechanisms. He received the Conquer Cancer Foundation ASCO Young Investigator Award in 2013 and is responsible for the ESMO European recommendations for bladder tumour management. He leads the EORTC urological tumours research group and has authored more than 300 publications in high-impact journals including the New England Journal of Medicine.